Nzolo Didier, Anto Francis, Hailemariam Sarah, Bakajika Didier, Muteba Daniel, Makenga Jean-Claude, Mesia Gautier, Nsibu Celestin, Mampunza Samuel, Tona Gaston
School of Public Health, University of Ghana, Legon, Accra, Ghana.
Unit of Clinical Pharmacology and Pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
Drugs Real World Outcomes. 2017 Sep;4(3):151-158. doi: 10.1007/s40801-017-0110-0.
The mainstay of onchocerciasis control currently is mass administration of ivermectin; however, this may be associated with serious adverse events, including deaths, when administered in areas where onchocerciasis and loiasis are co-endemic.
The objective of the current study was to describe the central and peripheral nervous system disorders that occurred after mass administration of ivermectin in Democratic Republic of Congo (DRC).
This is a retrospective descriptive study involving a review of data on adverse events related to mass administration of ivermectin. Data on reported serious adverse events following mass administration of ivermectin in the DRC were extracted from the World Health Organization (WHO) Global individual case safety report (ICSR) database (VigiBase). The review covered the period 2009-2013 and focused on central and peripheral nervous system disorders. Relevant demographic, clinical, and parasitological data, including age, sex, area of residence, adverse events, and parasite density were extracted. Descriptive statistics were analyzed using Stata 12.
A total of 52 ICSRs related to ivermectin intake were available in VigiBase, with 51 (98.1%) from the Province of Equateur. All patients had central and peripheral nervous system disorders; 25 (48.1%) had altered mental status. Of these, 23 (92.0%) satisfied the criteria for "probable/possible Loa loa encephalopathy temporally related to mectizan" (PLERM). The most frequent nervous system disorders among patients with PLERM were coma (74%), stupor (30%), headache (22%), and abnormal gait (22%). There were, on average, 2149.1 microfilariae per ml (mf/ml) in peripheral blood [95% confidence interval (CI) 463.6-3834.6; n = 23]. Post-treatment, 61% of PLERM cases had <1000 L. loa mf/ml of blood. One patient had microfilariae in the cerebrospinal fluid rather than the peripheral blood. We found 21.4% co-infection with Plasmodium falciparum and 4% mortality.
PLERM may occur at even low peripheral blood concentrations of microfilaria.
目前盘尾丝虫病控制的主要手段是大规模服用伊维菌素;然而,在盘尾丝虫病和罗阿丝虫病共同流行的地区服用时,这可能会引发包括死亡在内的严重不良事件。
本研究的目的是描述在刚果民主共和国大规模服用伊维菌素后发生的中枢神经系统和周围神经系统疾病。
这是一项回顾性描述性研究,涉及对与大规模服用伊维菌素相关的不良事件数据进行审查。从世界卫生组织(WHO)全球个体病例安全报告(ICSR)数据库(VigiBase)中提取刚果民主共和国大规模服用伊维菌素后报告的严重不良事件数据。审查涵盖2009 - 2013年期间,重点关注中枢神经系统和周围神经系统疾病。提取了相关的人口统计学、临床和寄生虫学数据,包括年龄、性别、居住地区、不良事件和寄生虫密度。使用Stata 12进行描述性统计分析。
VigiBase中共有52份与伊维菌素摄入相关的ICSR,其中51份(98.1%)来自赤道省。所有患者均患有中枢神经系统和周围神经系统疾病;25例(48.1%)出现精神状态改变。其中,23例(92.0%)符合“与美克太尔时间相关的可能/疑似罗阿丝虫脑病”(PLERM)标准。PLERM患者中最常见的神经系统疾病是昏迷(74%)、木僵(30%)、头痛(22%)和步态异常(22%)。外周血中平均每毫升有2149.1条微丝蚴(mf/ml)[95%置信区间(CI)463.6 - 3834.6;n = 23]。治疗后,61%的PLERM病例血液中罗阿丝虫微丝蚴<1000 mf/ml。1例患者脑脊液中有微丝蚴而非外周血。我们发现21.4%的患者合并感染恶性疟原虫,死亡率为4%。
即使外周血微丝蚴浓度较低时也可能发生PLERM。